{"entity":{"id":"nct05423262","kind":"trial","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TRK-950, Nivolumab in melanoma, run by Toray Industries, Inc, now recruiting.","summary":"A Study of TRK-950 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05423262 by Toray Industries, Inc, with 49 participants planned, started 2022-07-06 and due to reach its primary completion in 2027-12. Interventions recorded: TRK-950, TRK-950, TRK-950, Nivolumab, TRK-950. Conditions listed: Solid Tumor, Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05423262","url":"https://clinicaltrials.gov/study/NCT05423262"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["trk-950","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05423262","phase":"1/2","setting":"A Phase I/II Study of TRK-950 in Patients With Advanced Solid Tumors","sponsor":"Toray Industries, Inc","enrolled":49,"outcomes":[]},"route":"/trials/nct05423262/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"trk-950","kind":"drug","name":"TRK-950","route":"/drugs/trk-950/"}]}}